Gemtuzumab ozogamicin: is there room for salvage?

被引:18
作者
Clarke, W. Thomas [1 ]
Marks, PeterW. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
关键词
ACUTE MYELOID-LEUKEMIA; MYLOTARG; THERAPY; TRIAL;
D O I
10.1182/blood-2010-08-300871
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2618 / 2619
页数:2
相关论文
共 7 条
[1]  
Bross PF, 2001, CLIN CANCER RES, V7, P1490
[2]   Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia [J].
Chowdhury, Saeeda ;
Seropian, Stuart ;
Marks, Peter W. .
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (09) :599-600
[3]  
DILLMAN RO, 1991, BLOOD, V78, P2520
[4]  
Giles Francis J, 2002, Expert Rev Anticancer Ther, V2, P630, DOI 10.1586/14737140.2.6.630
[5]   Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia [J].
Lo-Coco, F ;
Cimino, G ;
Breccia, M ;
Noguera, NI ;
Diverio, D ;
Finolezzi, E ;
Pogliani, EM ;
Di Bona, E ;
Micalizzi, C ;
Kropp, M ;
Venditti, A ;
Tafuri, A ;
Mandelli, F .
BLOOD, 2004, 104 (07) :1995-1999
[6]   A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group [J].
Rowe, JM ;
Neuberg, D ;
Friedenberg, W ;
Bennett, JM ;
Paietta, E ;
Makary, AZ ;
Liesveld, JL ;
Abboud, CN ;
Dewald, G ;
Hayes, FA ;
Tallman, MS ;
Wiernik, PH .
BLOOD, 2004, 103 (02) :479-485
[7]   High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group [J].
Taksin, A-L ;
Legrand, O. ;
Raffoux, E. ;
de Revel, T. ;
Thomas, X. ;
Contentin, N. ;
Bouabdallah, R. ;
Pautas, C. ;
Turlure, P. ;
Reman, O. ;
Gardin, C. ;
Varet, B. ;
de Botton, S. ;
Pousset, F. ;
Farhat, H. ;
Chevret, S. ;
Dombret, H. ;
Castaigne, S. .
LEUKEMIA, 2007, 21 (01) :66-71